A multicenter, double-blind, dose-ranging, randomized, placebo- controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of genant and larsen scores

Arthritis and Rheumatism

Volumn 43, Issue 5, 2000, Pages 1001-1009

  Jiang, Yebin ^e   Genant, Harry K ^d   Watt, Iain ^a   Cobby, Mark ^a   Bresnihan, Barry ^b   Aitchison, Roger ^c   McCabe, Dorothy ^c  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c AMGEN INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; BONE EROSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HAND RADIOGRAPHY; HUMAN; JOINT CAVITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

NON-PROGRAMMATIC;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; PLACEBOS; RECEPTORS, INTERLEUKIN-1; RECOMBINANT PROTEINS; SIALOGLYCOPROTEINS;

EID: 0034083128     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P     Document Type: Article

References (41)

1. Sharp JT. Radiologic assessment as an outcome measure in rheumatoid arthritis. Arthritis Rheum 1989;32:221-9.
2. Genant HK, Jiang Y, Peterfy C, Lu Y, Rédei J, Countryman PJ. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum 1998;41:1583-90.
3. Sharp JT, Lidsky MD, Collins LS, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis: correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971;14:706-20.
4. Genant HK. Methods of assessing radiographic change in rheumatoid arthritis. Am J Med 1983;75:35-47.
5. Fries JF, Bloch DA, Sharp JT, McShane DJ, Spitz P, Bluhm GB, et al. Assessment of radiologie progression in rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 1986;29:1-9.
6. Larsen A, Thoen J. Hand radiography of 200 patients with rheumatoid arthritis repeated after an interval of one year. Scand J Rheumalol 1987;16:395-401.
7. Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989;16:585-91.
8. Pincus T, Callahan LF, Fuchs HA, Larsen A, Kaye J. Quantitative analysis of hand radiographs in rheumatoid arthritis: time course of radiographic changes, relation to joint examination measures, and comparison of different scoring methods. J Rheumatol 1995; 22:1983-9.
9. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-62.
10. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 1977;8:481-91.
11. Sharp JT, Young DY, Bluhm GB, Brook A, Brower AC, Corbett M, et al. How many joints in the hands and wrists should be included in a score of radiologie abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 1985:28:1326-35.
12. Arend WP, Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor a in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
13. Van de Loo FAJ, Joosten LAB, van Lent PLEM, Arntz OJ, van den Berg WB. Role of interleukin-1, tumor necrosis factor α, and interleukin-6 in cartilage, proteoglycan metabolism and destruction: effect of in situ blocking of murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995;38:164-72.
14. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 1988;2:706-9.
15. Kahle P, Saal JG, Schaudt K, Zacher J, Fritz P, Pawele G. Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue. Ann Rheum Dis 1992;51:731-4.
16. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147.
17. Van Lent PLEM, van de Loo FAJ, Holthuysen AEM, van den Bersselaar LAM, Vermeer H, van den Berg WB. Major role for interleukin 1 but not tumor necrosis factor in early cartilage damage in immune complex arthritis in mice. J Rheumatol 1995; 22:2250-8.
18. Hutchinson NI, Lark MW, MacNaul KL, Harper C, Hoerrner LA, McDonnell J, et al. In vivo expression of stromelysin in synovium and cartilage of rabbits injected intraarticularly with interleukin-1β. Arthritis Rheum 1992;35:1227-33.
19. Arend WP, Welgus HG, Thompson RC, Eisenberg SP. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest 1990;85:1694-7.
20. Pelletier J-P. Caron JP, Evans C, Robbins PD, Georgescu HI, Jovanovic D, et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997;40:1012-9.
21. Bakker AC, Joosten LAB, Arntz OJ, Helsen MMA, Bendele AM, van de Loo FAJ, et al. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum 1997;40:893-900.
22. Chole RA, Faddis BT, Tinling SP. In vivo inhibition of localized bone resorption by human recombinant interleukin-1 receptor antagonist. J Bone Miner Res 1995;10:281-4.
23. Kimble RS, Vannice JL, Blocdow DC, Thompson RC, Hopfer W, Kung VT, et al. Interleukin-1 receptor antagonist decreases hone loss and bone resorption in ovariectomized rats. J Clin Invest 1994;93:1959-67.
24. Campion GV, Lesback ME, Lookabaugh J, Gordon G, Catalano M, and the II-IRa Arthritis Study Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1092-101.
25. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41:2196-204.
26. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
27. Genant HK, Kirby DS, Pickering EA, Loose LD, Weiner ES, Ting N. Tenidap slows x-ray deterioration in rheumatoid arthritis [abstract]. Arthritis Rheum 1995;38 Suppl 9:S330.
28. Genant HK, Rédei J, Ouyang X, Countryman PJ. CD-ROM-based high-resolution digital image workstation for multicenter rheumatoid arthritis drug trials. Zurich: EULAR; 1997.
29. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
30. Geusens P, Wouters C, Nijs J, Jiang Y, Dequcker J. Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis: a 12-month, double-blind, controlled study. Arthritis Rheum 1994;37:824-9.
31. Peterfy CG, Dion E, Mias Y, White DL, Jiang Y, Genant HK. MRI is twice as sensitive as radiography for monitoring progression of bone erosion in rheumatoid arthritis [abstract]. Radiology 1998;209:500.
32. Sharp JT, Bluhm GB, Brook A, Brower AC, Corbett M, Decker JL, et al. Reproducibility of multiple-observer scoring of radiologic abnormalities in the hands and wrists of patients with rheumatoid arthritis. Arthritis Rheum 1985;28:16-24.
33. Jiang Y, Peterfy C, Lu Y, Redei J, Countryman P, Genant HK. Semiquantitative scoring of high-resolution laser-digitized images versus original conventional radiographs in patients with rheumatoid arthritis [abstract]. Radiology 1998;206:857.
34. Weinblatt ME, Polisson R, Blotner SD, Sosman JL, Aliabadi P, Baker N, et al. The effects of drug therapy on radiographic progression of rheumatoid arthritis: results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis Rheum 1993;36:613-9.
35. Pincus T. Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trial. J Clin Epidemiol 1988; 41:1037-41.
36. Multicentre Trial Group. Controlled trial of D-penicillamine in severe rheumatoid arthritis. Lancet 1973;1:275-80.
37. Borg G, Allander E, Berg E. Auranofin treatment in early rheumatoid arthritis may postpone early retirement: results from a 2-year double blind trial. J Rheumatol 1991;18:1015-20.
38. Scott DL, Grindulis KA, Struthers GR, Coulton BL, Popert AJ, Bacon PA. Progression of radiologie changes in rheumatoid arthritis. Ann Rheum Dis 1984;43:8-17.
39. Paulus HE, Egger MJ, Ward JR, Williams HJ. and the Cooperative Systematic Studies of Rheumatic Diseases Group. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990;33:477-84.
40. Van der Heijde DMFM, van Leeuwen MA, van Riel PLCM, Koster AM, van 't Hof MA, van Rijswijk MH, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992;35:26-34.
41. Sharp JT. Radiographic evaluation of the course of articular disease. Clin Rheum Dis 1983;9:541-57.